Evidence map›Paper›PMID 26898552›Full record

ReviewCellular and molecular neurobiology2016

The Utility of Cerebral Blood Flow as a Biomarker of Preclinical Alzheimer's Disease.

Chelsea C Hays, Zvinka Z Zlatar, Christina E Wierenga

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in Cellular and molecular neurobiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05396287 (The Impact of Cerebral Anatomical Variations on Cerebrovascular Reactivity), which is not on this map. Cited by 120 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed, 2 pooled it
21.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05396287 active not recruitingnot on this mapstarted 2022, after this paper: background citation

The Impact of Cerebral Anatomical Variations on Cerebrovascular Reactivity

TypeobservationalSponsorUniversity of Wisconsin, MadisonRan2022 to 2027Enrolled80ConditionsBrain Blood Flow, HealthyArmsMRI
3 · Its place in the literature

Who cites it

120 citing papers in PubMed, 2 syntheses or guidelines pooled it, 211 citations in OpenAlex.

  1. Dynamic cerebral autoregulation in Alzheimer's disease and mild cognitive impairment: A systematic review.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023
    Pooled it
  2. Pooled it
  3. A phase 2A/B randomized trial of metabolic modulators intranasal insulin and empagliflozin for MCI and early AD.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Amyloid β alters vascular CaThe Journal of physiology · 2025
    Article
  9. Article
  10. Review
  11. Blockade of AGeroScience · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Frontiers in global women's health · 2025
    Article
  19. Review
  20. Vascular Function and Ion Channels in Alzheimer's Disease.Microcirculation (New York, N.Y. : 1994) · 2024
    Review

60 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Chelsea C HaysVA San Diego Healthcare System, 3350 La Jolla Village Dr., MC 151B, San Diego, CA, 92161, USA.
Zvinka Z ZlatarVA San Diego Healthcare System, 3350 La Jolla Village Dr., MC 151B, San Diego, CA, 92161, USA.
Christina E WierengaVA San Diego Healthcare System, 3350 La Jolla Village Dr., MC 151B, San Diego, CA, 92161, USA. cwierenga@ucsd.edu.
San Diego State University · USUniversity of California, San Diego · USVA San Diego Healthcare System · US

Funding

FELLOWSHIP IN GERIATRIC MENTAL HEALTHT32MH019934 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Elizabeth W Twamley · 1994 to 2026
$9.5M
Cognitive and Brain Changes in Preclinical Alzheimer's DiseaseI01CX000565 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI WIERENGA, CHRISTINA E · 2013 to 2022
–
CSRD VA I01 CX000565NIMH NIH HHS T32 MH019934
6 · The paper itself

Abstract

There is accumulating evidence suggesting that changes in brain perfusion are present long before the clinical symptoms of Alzheimer's disease (AD), perhaps even before amyloid-β accumulation or brain atrophy. This evidence, consistent with the vascular hypothesis of AD, implicates cerebral blood flow (CBF) in the pathogenesis of AD and suggests its utility as a biomarker of preclinical AD. The extended preclinical phase of AD holds particular significance for disease modification, as treatment would likely be most effective in this early asymptomatic stage of disease. This highlights the importance of identifying reliable and accurate biomarkers of AD that can differentiate normal aging from preclinical AD prior to clinical symptom manifestation. Cerebral perfusion, as measured by arterial spin labeling magnetic resonance imaging (ASL-MRI), has been shown to distinguish between normal controls and adults with AD. In addition to demonstrating diagnostic utility, CBF has shown usefulness as a tool for identifying those who are at risk for AD and for predicting subtle cognitive decline and conversion to mild cognitive impairment and AD. Taken together, this evidence not only implicates CBF as a useful biomarker for tracking disease severity and progression, but also suggests that ASL-measured CBF may be useful for identifying candidates for future AD treatment trials, especially in the preclinical, asymptomatic phases of the disease.

Indexed as

AgingAlzheimer DiseaseBiomarkersCerebrovascular CirculationGenetic Predisposition to DiseaseHumansRisk FactorsBiomarkersAlzheimer’s diseaseArterial spin labelingCerebral blood flowMild cognitive impairmentNeuroimagingPerfusion

Identifiers

PMID26898552
PMCPMC5278904
OpenAlexW2283957277

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.